Live Breaking News & Updates on Silicon Therapeutics

Stay updated with breaking news from Silicon therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adding Chemotherapy to Osimertinib Improves PFS in EGFR-Mutant, Advanced NSCLC

Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for EGFR-mutant, advanced NSCLC, phase 3 data suggest. ....

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Daiichi-sankyo , Eli-lilly , Roche-genentech , Astellas-pharmaceuticals , Gatekeeper-pharmaceuticals , Boehringer-ingelheim , Pfizer , Novartis

ENLIVEX THERAPEUTICS : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K -September 13, 2023 at 04:45 pm EDT

ENLIVEX THERAPEUTICS LTD.

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

To be held on October 26, 2023

Dear Shareholder:

We. ....

Ness-ziona , Hamerkaz , Israel , France , Belgium , Greece , South-africa , Pretoria , Gauteng , Spain , Massachusetts , United-states

Attorneys – Malpractice – Expert evidence | Massachusetts Lawyers Weekly

Attorneys – Malpractice – Expert evidence | Massachusetts Lawyers Weekly
masslawyersweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from masslawyersweekly.com Daily Mail and Mail on Sunday newspapers.

Stanley-feldman , Nancyj-moore , Finith-jernigan , Geraldp-oconnor , Silicon-therapeutics , Paul-gompers , Professor-nancy , Attorney-gerald , Chengwei-capital ,

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma ....

Astellas-pharma , Immatics-incyte , Crown-bioscience , Jason-luke , Immunocore-incyte , Pembrolizumab-keytruda , Trex-bio , Codiak-biosciences , Bristol-myers-squibb , Serono , Novartis , Pfizer

Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance. ....

Copenhagen , Køavn , Denmark , Switzerland , Geneva , Genè , Monte-rosa , Daiichi-sankyo , Adagrasib-krazati , Roche-genentech , Eli-lilly , Lowe-center